Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Manresa
Clinical trial register · Spain

Clinical Trials in Manresa, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
UNICANCER3 Pfizer3 Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa3 AbbVie2 Spanish Breast Cancer Research Group2
Site location
Barcelona3238 Madrid3046 Valencia1215 Seville1054 Málaga746
All 453 locations
Target enrolment
to

Trials with a site in Manresa

50 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Not yet open
Immersive VR to Reduce Stress, Anxiety, and Pain During PICC/Midline Placement
NCT07696156Vasoconstriction, Biomarkers, Central Venous Catheters, Midline Catheter
DrugChlorhexidine Gluconate
diana garcia
Not applicable
202
Barcelona, Manresa, Girona
2027-01-15
Recruiting
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
NCT07106632Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer
UNICANCER
Phase 3
3,380
Alicante, Barcelona, Castillón, Granada, Madrid, Manresa, Palma, Seville
2026-06-26
Recruiting
Rovi Pharmaceuticals Laboratories
Phase 1
120
Alcorcón, Barcelona, Granada, Jaén, León, Lleida, Manresa, Málaga
2026-06-08
Recruiting
Novo Nordisk A/S
Phase 3
2,500
A Coruña, Antequera, Barcelona, Centelles (Barcelona), Girona, Madrid, Manresa, Málaga
2026-05-21
Recruiting
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
NCT07242547Limited-stage Small-cell Lung Cancer, Carcinoma, Small Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms
DrugTarlatamab
Fundación GECP
Phase 2
37
Albacete, Alicante, Elche, Barcelona, Manresa, Bilbao, Jerez de la Frontera, Lugo
2026-05-20
Recruiting
i+Med S.Coop.
Not applicable
300
Barcelona, Manresa, Bilbao
2026-04-29
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
118
Badajoz, Badalona, Barcelona, Girona, Madrid, Manresa, Seville, Valencia
2026-03-31
Recruiting
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Not applicable
120
Manresa
2026-02-18
Recruiting
Efficacy and Safety of Transcutaneous Posterior Tibial Nerve Stimulation on Fecal Continence in Patients Undergoing Surgery for Rectal Neoplasia
NCT07632196Low Anterior Resection Syndrome (LARS), Rectal Neoplasm Malignant, Quality of Life (QOL), Fecal Incontinence (FI)
Althaia Xarxa Assistencial Universitària de Manresa
Not applicable
84
Manresa
2026-02-06
Recruiting
CSL Behring
Phase 2
84
Badalona, Barcelona, LAS Palmas de GC, Madrid, Majadahonda, Manresa, Seville
2026-01-22
Recruiting
Janssen Research & Development, LLC
Phase 3
258
Barcelona, Esplugues de Llobregat, Madrid, Manresa, Oviedo, Pamplona, Sabadell
2026-01-08
Active, closed
Early Neuropsychological Rehabilitation and Family Psychoeducation After Ischemic Stroke
NCT07793682Ischemic Stroke, Cognitive Impairment, Quality of Life, Caregiver Burden
Althaia Xarxa Assistencial Universitària de Manresa
Not applicable
81
Manresa
2025-11-19
Not yet open
Validation and Evaluation of the Mastication Function in Adults: The Functional Six-minute Mastication Test (F-6MMT).
NCT06298786Mastication Disorder, Fatigue, Temporomandibular Disorder, Orofacial Pain
Fundació Universitària del Bages
Observational
514
Manresa, Barcelona
2025-09
Recruiting
AstraZeneca
Phase 2
278
A Coruña, Madrid, Manresa, Málaga, Santander, Valencia
2025-08-07
Recruiting
Hoffmann-La Roche
Observational
700
Almería, Palma de Mallorca, Manresa, Puerto Real, Alcázar de San Juan, Santiago de Compostela, Oviedo, Reus
2025-07-15
Active, closed
AbbVie
Phase 3
573
Santiago de Compostela, Granollers, Manresa, Las Palmas de Gran Canaria, Alcorcón, Majadahonda, Gijón, Seville
2025-06-17
Not yet open
ENERGY2MOB STUDY: OBESITY MANAGEMENT IN BERGUEDÀ
NCT06988904Mediterranean Diet, Overweight or Obese Adults, Exercise Therapy, Cardiovascular Diseases
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Not applicable
136
Manresa
2025-06-07
Recruiting
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Observational
153
Vitoria-Gasteiz, Badalona, L'Hospitalet de Llobregat, Manresa, Mataró, Terrassa, Viladecans, Torrelavega
2025-04-14
Active, closed
Pfizer
Phase 3
600
L'Hospitalet de Llobregat, Barcelona, Madrid, Manresa, Valencia
2024-10-21
Recruiting
North Eastern German Society of Gynaecological Oncology
Phase 2
640
Alicante, Granada, Lugo, Madrid, Manresa, Seville, Tarragona, Valencia
2024-10-11
By invitation
European Association of Urology Research Foundation
Observational
20,000
Santiago de Compostela, Manresa
2024-06-01
Recruiting
Immunological Characteristics of Preclinical IBD
NCT05698745Crohn Disease, Ulcerative Colitis, IBD
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Observational
450
Santiago de Compostela, Badalona, Manresa, Terrassa, Donostia / San Sebastian, Vigo, Gijón, Oviedo
2024-06-01
Recruiting
Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
NCT06024109Abnormal Uterine Bleeding, Endometriosis, Uterine Prolapse, Uterine Cancer
Aesculap AG
Observational
132
Manresa
2024-03-19
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Badajoz, Badalona, Manresa, Girona, León, Lleida, Madrid, Pamplona
2023-11-16
Active, closed
AbbVie
Observational
146
Vitoria-Gasteiz, Manresa, Terrassa, Jerez de la Frontera, Laredo, Santander, Las Palmas de Gran Canaria, León
2023-11-06
Not yet open
Promoting a Healthy Life Through Gender Equity
NCT05963893Mental Health Wellness 1, Physical Inactivity, Sedentary Behavior, Gender Discrimination
Fundació Universitària del Bages
Observational
350
Manresa
2023-09-04
Recruiting
Hoth Therapeutics, Inc.
Phase 2
152
Manresa
2023-07-19
Active, closed
Regeneron Pharmaceuticals
Phase 2
51
Badalona, Manresa, Castellon, Madrid, Málaga, Pamplona, Valencia
2023-04-21
Recruiting
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Not applicable
40
Badalona, L'Hospitalet de Llobregat, Manresa, Sabadell, Sant Joan Despí, Terrassa, Cáceres, Girona
2022-11-29
Active, closed
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib
NCT05252988Early-stage Breast Cancer, HER2 Positive Breast Cancer, Hormone Receptor Positive
DrugsColesevelam·Loperamide·Neratinib
Spanish Breast Cancer Research Group
Phase 2
177
Elche, Málaga, Zaragoza, L'Hospitalet de Llobregat, Manresa, Mataró, Castellon, Valladolid
2022-08-31
Active, closed
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
NCT05403385Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
DrugsPemetrexed·Carboplatin
iTeos Therapeutics
Phase 2
36
Palma de Mallorca, Pamplona, Valencia, A Coruña, Badajoz, Barcelona, Manresa, Ourense
2022-08-26
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 2
256
Badajoz, Barcelona, Córdoba, Elche, Lugo, Madrid, Manresa
2022-08-17
Recruiting
Linkoeping University
Not applicable
750
Barcelona, Manresa, Valencia
2022-05-16
Recruiting
UNICANCER
Phase 3
300
Badalona, Barcelona, Girona, Madrid, Manresa, Valencia
2022-04-19
Recruiting
Spanish Registry of Patients With IgM Monoclonal Gammopathies
NCT05093153Waldenstrom Macroglobulinemia
Fundación Española de Hematología y Hemoterapía
Observational
1,000
Mérida, Palma, Palma de Mallorca, Badalona, Barcelona, Manresa, Sabadell, Córdoba
2021-10-01
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Elche, Palma de Mallorca, Badalona, Manresa, Sabadell, Santiago de Compostela, Jerez de la Frontera, Castellon de LA Plana/castello de LA Plana
2021-08-27
Recruiting
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
NCT04889924Breast Cancer, Chemotherapy, Sentinel Lymph Node, Axillary Lymph Nodes Dissection
Hospital Universitari de Bellvitge
Not applicable
820
Badalona, Calella, Granollers, L'Hospitalet de Llobregat, Manresa, Mataró, Sant Cugat del Vallès, Terrassa
2021-06-11
Active, closed
Pfizer
Phase 3
599
Elche, Badalona, L'Hospitalet de Llobregat, Manresa, Lugo, Majadahonda, Pamplona, Oviedo
2021-05-12
Recruiting
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis
AgNovos Healthcare, LLC
Not applicable
2,400
Barcelona, Valladolid, Bilbao, Galdakao, Jaén, Madrid, Manresa, Sabadell
2021-04-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Badalona, Manresa, Girona, Santiago de Compostela, Las Palmas de Gran Canaria, Oviedo, Valencia, Barcelona
2021-04-21
Active, closed
Exelixis
Phase 3
575
Elche, Palma de Mallorca, Manresa, Santiago de Compostela, Alcorcón, Oviedo, Badalona, Barcelona
2020-10-19
Active, closed
Women's Cancer Study Group GmbH
Phase 3
1,260
Palma, Barcelona, Cáceres, Elche, Madrid, Manresa, Málaga, Pamplona
2020-09-02
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Barcelona, Córdoba, Lugo, Madrid, Manresa, Pamplona, Sabadell, Santander
2020-03-30
Active, closed
Spanish Oncology Genito-Urinary Group
Phase 2
39
Manresa, Sabadell, Reus, Granada, Lugo, Madrid, Ourense, Oviedo
2019-09-18
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Elche, Granada, Huelva, Jaén, Vitoria-Gasteiz, Badalona, L'Hospitalet de Llobregat, Manresa
2018-12-07
Active, closed
Gilead Sciences
Phase 2
502
Badalona, Barcelona, Córdoba, Las Palmas, Madrid, Majadahonda, Manresa, Ourense
2018-08-13
Active, closed
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
DrugsTisotumab Vedotin·Tivdak·Keytruda·Cisplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
350
Barcelona, Manresa, Madrid
2018-06-25
Recruiting
Spanish Breast Cancer Research Group
Observational
1,867
Elche, Manresa, Terrassa, San Sebastián, Las Palmas de Gran Canaria, Alcorcón, Fuenlabrada, Leganés
2016-08
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Palma de Mallorca, Manresa, Santiago de Compostela, Barcelona, Cadiz, Girona, Madrid, Ourense
2014-12-17
Active, closed
UNICANCER
Phase 3
1,173
Badalona, Barcelona, Girona, Madrid, Manresa, Málaga, Sabadell, Salamanca
2013-11-13
Rows per page Showing 1–50 of 50
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/manresa

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 50 of those studies with a site in Manresa.

How many clinical trials are recruiting in Manresa?

24 of the 50 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 4 have not yet opened recruitment, 21 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Manresa), 50 studies
PhaseStudiesRecruitingShare
Phase 316432%
Phase 212524%
Not applicable10720%
Observational10620%
Phase 1112%
Phase 1/2112%

Most active sponsors

Lead sponsors with the most studies (Manresa)
Lead sponsorStudiesRecruiting
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa33
Pfizer30
UNICANCER32
AbbVie20
Althaia Xarxa Assistencial Universitària de Manresa21
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina21
Fundació Universitària del Bages20
Hoffmann-La Roche21
Spanish Breast Cancer Research Group21
Aesculap AG11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.